A new vision for quality of care


The Peer Kidney Care Initiative (“Peer”) is a collaborative quality initiative that leverages public and private data sources to inform patients, physicians, dialysis provider organizations, payers, and state and federal governments about the past, present, and future states of dialysis patient care.

The mission of Peer is to improve the quality of dialysis patient care in the United States. The academic researchers of Peer and the Chief Medical Officers of participating dialysis provider organizations together will analyze and interpret real-world data to identify contemporary patterns of treatment, historical trends in clinical outcomes, and both regional and national opportunities for quality improvement. Peer aims to elucidate the complex interaction of all health care providers that touch patients, including dialysis facilities, hospitals, pharmacies, and physician practices. Peer also aims to offer an alternative voice in the formation of policy that affects both patients and their health care providers.

As parts of its outreach, Peer is committed to disseminating its work at www.peerkidney.org, in presentations during conferences and meetings, and with studies published in academic journals.


Financial support for Peer is provided by 13 participating dialysis provider organizations: American Renal Associates, Atlantic Dialysis Management Services, Centers for Dialysis Care, DaVita HealthCare Partners, Dialysis Clinic, Inc. (DCI), DSI Renal, Fresenius Medical Care, Independent Dialysis Foundation, Northwest Kidney Centers, Renal Ventures Management, Satellite Healthcare, The Rogosin Institute, and U.S. Renal Care.

In collaboration with the Chief Medical Officers of these organizations, the Peer Kidney Care Initiative is operated by the Chronic Disease Research Group, a division of the Minneapolis Medical Research Foundation, in Minneapolis, Minnesota. Allan Collins, MD, FACP, is the Executive Director of Peer. Regarding conflicts of interest, Allan Collins serves as a co-investigator on Phase I and II studies for DaVita Clinical Research.